Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
A MULTICENTER OBSERVATIONAL RETROSPECTIVE STUDY OF SECOND-LINE TREATMENT WITH DARATUMUMAB – BORTEZOMIB - DEXAMETHASONE (DaraVd) IN MULTIPLE MYELOMA (MM) PATIENTS REFRACTORY TO LENALIDOMIDE
Ilaria Rizzello, MD, PhD (she/her/hers)
MD, PhD
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”
Bologna, Emilia-Romagna, Italy